ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.94575
0.01%
Brent Oil
83.79
0.30%
Bitcoin
57,616.08
-1.07%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. FibroGen Inc (FGEN)

  7. FibroGen Inc (FGEN) Noticias

FGEN FibroGen Inc

1.20
0.08 (7.14%)
01 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
FibroGen Inc FGEN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.08 7.14% 1.20 16:21:51
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.12 1.09 1.2168 1.17 1.12
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202406:00GLOBEFibroGen to Report First Quarter 2024 Financial Results
24/4/202415:02GLOBEFibroGen Announces Clinical Data from Dose Escalation Phase..
02/4/202416:46GLOBEFibroGen Announces Topline Results from Phase 1 Monotherapy..
26/3/202406:00GLOBEFibroGen to Present at 23rd Annual Needham Virtual..
11/3/202406:00GLOBEFibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
08/3/202418:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202418:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202418:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:08EDGAR2Form 8-K - Current report
26/2/202415:06GLOBEFibroGen Reports Fourth Quarter and Full Year 2023 Financial..
26/2/202415:05GLOBEFibroGen Regains All Rights to Roxadustat from AstraZeneca..
23/2/202419:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202419:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202419:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202406:00GLOBEFibroGen to Report Fourth Quarter and Full Year 2023..
14/2/202414:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202419:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202406:00GLOBEFibroGen To Host Part I of Virtual KOL Investor Event Series..
25/1/202406:00GLOBEFibroGen Announces Completion of the Pamrevlumab Arm in..
26/12/202318:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202315:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202316:02GLOBEFibroGen Presents Data from Phase 3 MATTERHORN Trial of..
06/11/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202315:05EDGAR2Form 8-K - Current report
06/11/202315:01GLOBEFibroGen Reports Third Quarter 2023 Financial Results
03/11/202315:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/10/202315:30EDGAR2Form 8-K - Current report
23/10/202306:00GLOBEFibroGen to Report Third Quarter 2023 Financial Results
25/9/202318:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202316:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202315:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202315:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202319:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202319:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202307:55EDGAR2Form 8-K - Current report
01/9/202318:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202318:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202316:31EDGAR2Form 144 - Report of proposed sale of securities
29/8/202316:14EDGAR2Form 8-K - Current report
29/8/202315:15GLOBEFibroGen Announces Topline Results from LELANTOS-2, a Phase..
14/8/202316:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202316:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202318:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202315:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/8/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202315:06EDGAR2Form 8-K - Current report
07/8/202315:01GLOBEFibroGen Reports Second Quarter 2023 Financial Results

Su Consulta Reciente

NASDAQ
FGEN
FibroGen
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados